Two separate shareholder groups have filed suit to overturn a proposed $210 million buyout of Aspect Medical Systems Inc. by Covidien plc.
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ Analysts see $400B BCI opportunity
+ The top 10 neurotech stories of the year so far
+ 7 neurotech companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ 7 brain-computer interface companies you need to know
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
Aspect Medical Systems shareholders sue to block Covidien buyout
Shareholders of Aspect Medical Systems Inc. filed a lawsuit to block a proposed $210 million acquisition by Covidien.
The deal would see the Mansfield, Mass.-based medical devices giant pay $12 per share for Aspect, a Norwood, Mass.-based maker of brain monitoring equipment that measures the effects of anesthesia and sedation.
InVivo Therapeutics sues Oregon Health & Science University over primate study
A lawsuit filed earlier this month by Invivo Therapeutics Inc.in the U.S. District Court for Massachusetts is shedding new light on the status of Cambridge, Mass.-based company’s quest to cure paralysis.
Deerfield Management cashes in on NxStage
A New York hedge fund specializing in medical-device and biotech plays has sold off 4.4 percent of its overall stake in NxStage Medical Inc.
Former Caliper CFO jumps to NeuroMetrix
NeuroMetrix Inc. tapped the former CFO at Caliper Life Sciences to be its finances chief, effective immediately.
The Waltham, Mass.-based nerve test equipment maker said Higgins, a 30-year life sciences veteran, started at Caliper in 2005. Prior to that, he began a stint in 1998 as operations vice president and CFO at test & measurement systems provider V.I. Technologies Inc., running its plasma manufacturing business until the company sold it in 2001. He also spent 13 years at Cabot Corp., rising to president of its Distrigas of Mass. subsidiary.
NeuroMetrix to raise nearly $19 million in stock sale
NeuroMetrix Inc. won commitments from institutional investors to buy about $18.7 million worth of its stock — 8,816,521 shares and warrants to purchase up to 8,375,695 additional shares — in a private placement for $2.12 per share.
The Waltham, Mass.-based nerve test equipment manufacturer said the offering is expected to close “later this week.”
It plans to use the cash to bolster its direct sales force in the U.S., boost its profile overseas, pay for clinical trials and get its lead potassium channel blocker compound to a Phase I milestone.
Study of cerebral aneurysm coiling has good news for Boston Scientific, J&J’s Cordis
A study evaluating the risks of re-treating brain aneurysms after endovascular coil embolization bore some good news for Boston Scientific and Johnson & Johnson’s Cordis Corp. subsidiary.
The study‘s authors — two of whom received grants or honoraria from the two device makers — examined the results in 311 cases in which patients were treated again after having coils implanted in their brains via catheter. The study indicated that the risk of death or permanent major disability was 1.28 percent, or just more than one in 100.
The study was published in Neurosurgery magazine.
NeuroMetrix slashes Q2 net loss, even as sales slide
NeuroMetrix Inc. took a big step forward during the second quarter, slashing its net loss by nearly 64 percent even as revenues dipped 17 percent.
The Waltham, Mass.-based nerve testing equipment maker posted $6.8 million in sales for the three months ended June 30, compared with $8.1 million during the same period last year.
Net losses went from $5.8 million during the year-ago quarter to $4.8 million during the second quarter of 2009, a 63.5 percent reduction in red ink.
Aspect Medical inks licensing deal, improves operating margin
Echoing the optimism at Thermo Fisher Scientific and Cynosure Inc., Aspect Medical Systems Inc. said its second-quarter results suggest signs of improvement ahead.
Aspect Medical Systems, Cleveland Clinic ink comparative effectiveness research pact
Aspect Medical Systems Inc. inked a five-year comparative effectiveness research deal with Cleveland Clinic to study clinical best practices for anesthesiology.
The Norwood brain monitoring equipment maker said the study, using data from the medical clinic’s electronic medical records system, will compare patient outcomes in more than 85,000 surgical procedures for such measures as 30-day and one-year mortality rates and duration of hospitalization.
MedGadget’s MedTech Monday: 3D brain map
BrainNavigator: An online atlas to browse brain structures: Elsevier just released the official version of the BrainNavigator online virtual brain browser, an application developed in cooperation with the Allen Institute for Brain Science. Featuring a 3D interactive video interface, as well as traditional slices from a variety of animal brains, the software is designed for quick identification of neuroanatomical structures for scientists studying the organ.